Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai

被引:15
作者
Cai, Xiaoshu [1 ]
Yang, Hui [2 ]
Genchev, Georgi Z. [1 ,3 ,4 ]
Lu, Hui [1 ,3 ,5 ,6 ]
Yu, Guangjun [1 ]
机构
[1] Shanghai Childrens Hosp, Ctr Biomed Informat, Shanghai, Peoples R China
[2] Walkiesoft Ltd, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, SJTU Yale Joint Ctr Biostat, Shanghai, Peoples R China
[4] Bulgarian Inst Genom & Precis Med, Sofia, Bulgaria
[5] Univ Illinois, Dept Bioengn, Chicago, IL USA
[6] Shanghai Jiao Tong Univ, Dept Bioinformat & Biostat, Shanghai, Peoples R China
基金
国家重点研发计划;
关键词
Rare disease; Economic burden; Shanghai; Cost of illness; RESOURCE UTILIZATION; MEDICAL COSTS; HEMOPHILIA; CHINA; CARE;
D O I
10.1186/s13023-019-1168-4
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: It is estimated that at present there are over 10 million rare disease patients in China. Recently an increased focus from policy perspective has been placed on rare diseases management. Improved disease definitions and the releases of local and national rare disease lists are some of the steps taken already. Despite these developments, few Chinese rare disease-related epidemiology and economic studies exist, thus hindering assessment of the true burden of rare diseases. For a rare disease with an effective treatment, this is a particularly important aspect due to the often-high cost associated. Objective: The goal of this study is to address the data scarcity on the subject of rare diseases economic impact in China. We aim to address an existing knowledge gap and to provide a timely analysis of the economic burden of 23 rare diseases in Shanghai, China. Methods: We utilized the data from the Health Information Exchange system of Shanghai and employed statistical modeling to analyze the economic burden of rare diseases with an effective treatment in Shanghai. Results: First, we described the actual direct medical expenditure and analyzed its associated factors. Second, we found age, disease type, number of complications, and payment type were significantly associated with rare disease medical direct costs. Third, a generalized linear model was employed to estimate the annual direct cost. The mean direct medical cost was estimated as yen 9588 (US$1521) for inpatients and yen 1060 (US$168) for outpatients, and was over yen 15 million (similar to US$2.4 million) per year overall. Conclusion: Our study is one of the first quantifying the economic burden of an extensive set of rare diseases in Shanghai and China. Our results can serve to inform healthcare-focused policy making, contribute to the increase of public awareness, and incentivize development of rare-disease strategies and treatments specific to the Chinese context.
引用
收藏
页数:10
相关论文
共 24 条
  • [1] Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
    Angelis, Aris
    Tordrup, David
    Kanavos, Panos
    [J]. HEALTH POLICY, 2015, 119 (07) : 964 - 979
  • [2] [Anonymous], 2015, Shanghai Statistical Yearbook
  • [3] Baumann Ulrich, 2003, J Cyst Fibros, V2, P84, DOI 10.1016/S1569-1993(03)00024-9
  • [4] Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
    Cannizzo, Sara
    Lorenzoni, Valentina
    Palla, Ilaria
    Pirri, Salvatore
    Trieste, Leopoldo
    Triulzi, Isotta
    Turchetti, Giuseppe
    [J]. RMD OPEN, 2018, 4
  • [5] Cui YZ, 2017, INTRACTABLE RARE DIS, V6, P148, DOI 10.5582/irdr.2017.01009
  • [6] Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis
    Darba, Josep
    Ascanio, Meritxell
    [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (04) : 379 - 384
  • [7] Review of 11 national policies for rare diseases in the context of key patient needs
    Dharssi, Safiyya
    Wong-Rieger, Durhane
    Harold, Matthew
    Terry, Sharon
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [8] National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap
    Feng, Shi
    Liu, Shuang
    Zhu, Chong
    Gong, Mengchun
    Zhu, Yicheng
    Zhang, Shuyang
    [J]. HUMAN GENE THERAPY, 2018, 29 (02) : 128 - 135
  • [9] Rare disease patients in China anticipate the sunlight of legislation
    Gao, Jianjun
    Song, Peipei
    Tang, Wei
    [J]. DRUG DISCOVERIES AND THERAPEUTICS, 2013, 7 (03) : 126 - 128
  • [10] How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017
    Guan, Xiaodong
    Zhang, Jingyuan
    Man, Chunxia
    Ni, Bingyu
    Shi, Luwen
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (06) : 2199 - 2205